LSTA vs. TXMD, BFRG, GDTC, CPIX, RNXT, LUMO, SYBX, QLI, BNTC, and SLGL
Should you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include TherapeuticsMD (TXMD), Bullfrog AI (BFRG), CytoMed Therapeutics (GDTC), Cumberland Pharmaceuticals (CPIX), RenovoRx (RNXT), Lumos Pharma (LUMO), Synlogic (SYBX), Qilian International Holding Group (QLI), Benitec Biopharma (BNTC), and Sol-Gel Technologies (SLGL). These companies are all part of the "pharmaceutical preparations" industry.
TherapeuticsMD (NASDAQ:TXMD) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.
TherapeuticsMD has higher revenue and earnings than Lisata Therapeutics.
Lisata Therapeutics' return on equity of -21.00% beat TherapeuticsMD's return on equity.
TherapeuticsMD received 380 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Lisata Therapeutics an outperform vote while only 62.46% of users gave TherapeuticsMD an outperform vote.
Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 440.54%. Given TherapeuticsMD's stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than TherapeuticsMD.
30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 1.2% of TherapeuticsMD shares are owned by insiders. Comparatively, 21.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
TherapeuticsMD has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500.
In the previous week, Lisata Therapeutics had 4 more articles in the media than TherapeuticsMD. MarketBeat recorded 10 mentions for Lisata Therapeutics and 6 mentions for TherapeuticsMD. TherapeuticsMD's average media sentiment score of 0.93 beat Lisata Therapeutics' score of 0.80 indicating that Lisata Therapeutics is being referred to more favorably in the news media.
Summary
Lisata Therapeutics beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks.
Get Lisata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lisata Therapeutics Competitors List
Related Companies and Tools
